Moreover, expression changes in CD105, TGFβ1, VEGF, HIF-1a and tumor vasculature in the presence of low and high doses of bevacizumab in nude mouse models and clinical specimens require further elucidation. This evidence concerns the gene HIF1A and neoplasm.